Sickle Cell Disease Treatment Market to Grow at a CAGR of 20.1% over 2023-2030; Increasing Prevalence of Sickle Cell Disorders to Fuel Industry Growth

The global sickle cell disease treatment market size was USD 2.25 billion in 2022. The market value is slated to rise from USD 2.73 billion in 2023 to USD 9.84 billion by 2030 at a CAGR of 20.1% during 2023-2030.

Fortune Business Insights™ presents this information in its report titled, “Sickle Cell Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Treatment Modality [Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy {Hydroxyurea and Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, FT-4202, and GBT021601)}], By End-user [Hospitals, Specialty Clinics, and Others], and Regional Forecast, 2023-2030”. Sickle Cell Disease (SCD) is a genetic ailment that can lead to several illnesses, including hemoglobin SS disease, hemoglobin sickle cell disease, sickle cell anemia, and others, which can distort red blood cells. This causes early cell death, which causes blood shortage as well as blood flow inhibition, resulting in blockage.

Decreased Sickle Cell Disease Treatment Demand amid the Pandemic Limited Market Growth

The COVID-19 pandemic negatively affected the sickle cell disease treatment market growth. Reallocation of healthcare resources for COVID-19 treatment hampered blood transfusion and bone marrow transplant segments’ growth in 2020. Decreased sickle cell disease treatment adoption among patients amid the pandemic restrained market expansion.

However, increased sales of sickle cell disease treatment drugs after the pandemic fueled market progress.

Emmaus Life Sciences, Inc. Entered into a Partnership with UpScript IP Holdings, LLC. to Offer Access to Endari

Emmaus Life Sciences, Inc. partnered with UpScript IP Holdings, LLC. (UpScript) in November 2021 to provide telehealth facilities to patients and increase full access to Endari. This strategy allowed the company to enhance its brand image and expand its consumer base. These tactics are enabling companies to expand their product lines and organizational goals.

Several Severities of the SCD to Foster Industry Growth

The increasing prevalence of SCD is affecting millions of people across the globe. For instance, In May 2022, according to the CDC, around 100,000 Americans were affected by the disease.

Adults and adolescents with sickle cell disease usually experience the painful complication called Vaso-occlusive Crisis (VOC). It brings on sudden severe pain episodes. Patients, including adults and children, must seek out urgent medical care. The rising adoption of highly essential treatment procedures to reduce the chances of VOCs is fostering market growth.

Increasing key market players’ focus on introducing the drugs to lessen the impact of these diseases and deal with the painful consequences associated with them. Moreover, increasing focus on developing effective sickle cell disease treatment solutions is expected to boost market expansion. These factors are likely to drive the market growth.

On the other hand, market growth is hampered by a lack of availability of SCD treatment options.

Prominent Players Inclined toward the Expansion of Businesses to Gain Traction

Key players in the market include Global Blood Therapeutics Inc. (Pfizer Inc.), Novartis AG, and Emmaus Medical, Inc. Global Blood Therapeutics Inc. (Pfizer Inc.) held a prominent market share in 2022 due to the company’s substantial sales from Oxbryta for SCD treatment.

Oxbryta saw a 57.5% increase in sales from the previous year, generating revenue of USD 195 million in 2021.

Notable Industry Development

• October 2022: Pfizer Inc. completed the acquisition of Global Blood Therapeutics Inc. This acquisition enhanced the company’s R&D for sickle cell disease therapy

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/sickle-cell-disease-treatment-market-101009

List of the Companies Profiled in the Report:

• Bristol-Myers Squibb Company (U.S.)


• Addmedica (France)


• Novartis AG (Switzerland)


• Global Blood Therapeutics, Inc. (Pfizer Inc.) (U.S.)


• Emmaus Medical, Inc. (U.S.)


• bluebird bio Inc. (U.S.)


• Agios Pharmaceuticals, Inc. (U.S.)

Further Report Findings-

• The market in the U.S. stood at USD 1.44 billion in 2022. Strong government backing and increasing collaborations are expected to foster the adoption of sickle cell disease treatments.


• The rest of the world is projected to expand at a significant CAGR in the forthcoming years. Growing awareness about SCD and the strong pipeline of branded drugs are boosting market development in the region.


• The blood transfusion segment registered the highest revenue in 2022. Increasing need for blood transfusion treatment solutions to manage stroke augmented segment growth.


• Hospitals held a significant global sickle cell disease treatment market share. The segment growth is attributed to a rise in hospital admissions for sickle cell disease treatment.

Table of Segmentation